Focus now on NNZ2591, page-2

Yes - Jon says that the trofinetide success was "just the start"....

And he is much more upbeat about NNZ-2591 - he initiated the captial raising last year in the off chance that the phase 3 trofinetide trials failed.
In hindsight - that was not necessary.

This is the statement that encourages me the most about Neuren...from Jon Pilcher himself...

Yes trofinetide and NNZ-2591 both originate from Dame Margaret Brimble's work in Auckland. They are analogs of two different molecules - glycine proline glutamate (GPE) and cyclic glycine proline (cGP) respectively. Each plays a role in the metabolism of IGF-1 in the brain. The desired outcome of using the power of IGF-1 in the brain is the same, but with a different mechanism to achieve it. They also have different properties as drugs, with 2591 clearly superior in a few ways.

GLTAH - 2022 with our 2 drugs this is going 2 be our year!